25 research outputs found
Recommended from our members
Identification of (+)-Erythro-Mefloquine as an Active Enantiomer with Greater Efficacy than Mefloquine against Mycobacterium avium Infection in Mice
Infection caused by Mycobacterium avium is common in AIDS patients who do not receive treatment with highly active antiretroviral therapy (HAART) or who develop resistance to anti-HIV therapy. Mefloquine, a racemic mixture used for malaria prophylaxis and treatment, is bactericidal against M. avium in mice. MICs of (+)-erythro-, (−)-erythro-, (+)-threo-, and (−)-threo-mefloquine were 32 μg/ml, 32 μg/ml, 64 μg/ml, and 64 μg/ml, respectively. The postantibiotic effect for (+)-erythro-mefloquine was 36 h (MIC) and 41 h for a concentration of 4× MIC. The mefloquine postantibiotic effect was 25 h (MIC and 4× MIC). After baseline infection was established (7 days), the (+)- and (−)-isomers of the diastereomeric threo- and erythro-α-(2-piperidyl)-2,8-bis(trifluoromethyl)-4-quinolinemethanol were individually used to orally treat C57BL/6 bg+/bg+ beige mice that were infected intravenously with M. avium. Mice were also treated with commercial mefloquine and diluent as controls. After 4 weeks of treatment, the mice were harvested, and the number of bacteria in spleen and liver was determined. Mice receiving (+)- or (−)-threo-mefloquine or (−)-erythro-mefloquine had numbers of bacterial load in tissues similar to those of untreated control mice at 4 weeks. Commercial mefloquine had a bactericidal effect. However, mice given the (+)-erythro-enantiomer for 4 weeks had a significantly greater reduction of bacterial load than those given mefloquine. Thus, (+)-erythro-mefloquine is the active enantiomer of mefloquine against M. avium and perhaps other mycobacteria
Evaluation of Arylimidamides DB1955 and DB1960 as Candidates against Visceral Leishmaniasis and Chagas' Disease: In Vivo Efficacy, Acute Toxicity, Pharmacokinetics, and Toxicology Studies
Arylimidamides (AIAs) have shown outstanding in vitro potency against intracellular kinetoplastid parasites, and the AIA 2,5-bis[2-(2-propoxy)-4-(2-pyridylimino)aminophenyl]furan dihydrochloride (DB766) displayed good in vivo efficacy in rodent models of visceral leishmaniasis (VL) and Chagas' disease. In an attempt to further increase the solubility and in vivo antikinetoplastid potential of DB766, the mesylate salt of this compound and that of the closely related AIA 2,5-bis[2-(2-cyclopentyloxy)-4-(2-pyridylimino)aminophenyl]furan hydrochloride (DB1852) were prepared. These two mesylate salts, designated DB1960 and DB1955, respectively, exhibited dose-dependent activity in the murine model of VL, with DB1960 inhibiting liver parasitemia by 51% at an oral dose of 100 mg/kg/day × 5 and DB1955 reducing liver parasitemia by 57% when given by the same dosing regimen. In a murine Trypanosoma cruzi infection model, DB1960 decreased the peak parasitemia levels that occurred at 8 days postinfection by 46% when given orally at 100 mg/kg/day × 5, while DB1955 had no effect on peak parasitemia levels when administered by the same dosing regimen. Distribution studies revealed that these compounds accumulated to micromolar levels in the liver, spleen, and kidneys but to a lesser extent in the heart, brain, and plasma. A 5-day repeat-dose toxicology study with DB1960 and DB1955 was also conducted with female BALB/c mice, with the compounds administered orally at 100, 200, and 500 mg/kg/day. In the high-dose groups, DB1960 caused changes in serum chemistry, with statistically significant increases in serum blood urea nitrogen, lactate dehydrogenase, aspartate aminotransferase, and alanine aminotransferase levels, and a 21% decrease in body weight was observed in this group. These changes were consistent with microscopic findings in the livers and kidneys of the treated animals. The incidences of observed clinical signs (hunched posture, tachypnea, tremors, and ruffled fur) were more frequent in DB1960-treated groups than in those treated with DB1955. However, histopathological examination of tissue samples indicated that both compounds had adverse effects at all dose levels.This work was supported by a grant from the Bill and Melinda Gates Foundation, contract N01-AI-60011 with SRI International from the National Institute of Allergy and Infectious Diseases, FIOCRUZ, and by Fundação Carlos Chagas Filho de Amparo a Pesquisa do Estado do Rio de Janeiro (FAPERJ) PPSUS, APQ1, and Pensa-Rio (16/2009-E-26/110-313/2010), Conselho Nacional Desenvolvimento cientÃfico e Tecnológico (CNPq), PDTIS/FIOCRUZ, and PROEP.
We thank the other members of the Consortium for Parasitic Drug Development for helpful discussions
Evaluation of Arylimidamides DB1955 and DB1960 as Candidates against Visceral Leishmaniasis and Chagas' Disease: In Vivo Efficacy, Acute Toxicity, Pharmacokinetics, and Toxicology Studies
ABSTRACT Arylimidamides (AIAs) have shown outstanding in vitro potency against intracellular kinetoplastid parasites, and the AIA 2,5-bis[2-(2-propoxy)-4-(2-pyridylimino)aminophenyl]furan dihydrochloride (DB766) displayed good in vivo efficacy in rodent models of visceral leishmaniasis (VL) and Chagas' disease. In an attempt to further increase the solubility and in vivo antikinetoplastid potential of DB766, the mesylate salt of this compound and that of the closely related AIA 2,5-bis[2-(2-cyclopentyloxy)-4-(2-pyridylimino)aminophenyl]furan hydrochloride (DB1852) were prepared. These two mesylate salts, designated DB1960 and DB1955, respectively, exhibited dose-dependent activity in the murine model of VL, with DB1960 inhibiting liver parasitemia by 51% at an oral dose of 100 mg/kg/day × 5 and DB1955 reducing liver parasitemia by 57% when given by the same dosing regimen. In a murine Trypanosoma cruzi infection model, DB1960 decreased the peak parasitemia levels that occurred at 8 days postinfection by 46% when given orally at 100 mg/kg/day × 5, while DB1955 had no effect on peak parasitemia levels when administered by the same dosing regimen. Distribution studies revealed that these compounds accumulated to micromolar levels in the liver, spleen, and kidneys but to a lesser extent in the heart, brain, and plasma. A 5-day repeat-dose toxicology study with DB1960 and DB1955 was also conducted with female BALB/c mice, with the compounds administered orally at 100, 200, and 500 mg/kg/day. In the high-dose groups, DB1960 caused changes in serum chemistry, with statistically significant increases in serum blood urea nitrogen, lactate dehydrogenase, aspartate aminotransferase, and alanine aminotransferase levels, and a 21% decrease in body weight was observed in this group. These changes were consistent with microscopic findings in the livers and kidneys of the treated animals. The incidences of observed clinical signs (hunched posture, tachypnea, tremors, and ruffled fur) were more frequent in DB1960-treated groups than in those treated with DB1955. However, histopathological examination of tissue samples indicated that both compounds had adverse effects at all dose levels
Role of embryonic prostaglandin H synthase-catalyzed free radical formation and reactive oxygen species-mediated macromolecular damage in chemical teratogenesis
grantor:
University of TorontoTeratogenic xenobiotics such as thalidomide, phenytoin and benzo[a]pyrene (B[a]P) may be bioactivated by prostaglandin H synthases (PHSs) to free radical reactive intermediates that initiate the formation of reactive oxygen species (ROS), which oxidatively damage cellular macromolecules. Using electron paramagnetic resonance spectrometry, the mechanism of free radical formation for phenytoin and related analogs was evaluated in an 'in vitro' system with purified PHS-1 and the free radical spin trapping agent alpha-phenyl-N-'t'-butylnitrone (PBN). PHS-catalyzed, carbon-centred free radical formation was detected for phenytoin and all its analogs. For phenytoin, both a putative unstable nitrogen-centered and a stable carbon-centered free radicals were detected, which were capable of oxidizing DNA. This provides the first direct chemical evidence for PHS-catalyzed bioactivation of phenytoin and related teratogens to a free radical intermediate that initiates DNA oxidation, which may constitute a common molecular mechanism of teratologic initiation. The developmental role of PHS-1 and -2 is poorly understood. Using PHS-2 knockout mice, we determined that embryonic PHS-2 is expressed constitutively during organogenesis, and contributes substantially to B[a]P bioactivation and teratogenicity, evidenced by an increased incidence of malformations and postpartum lethality in both +/+ and +/- fetuses exposed 'in utero' to B[a]P compared to their -/- littermates. Similarly, PHS-1 knockout mice were less susceptible to phenytoin- and B[a]P-initiated embryopathy, and to phenytoin-initiated DNA oxidation. Although deficiencies in PHS-1 and -2 protected against xenobiotic teratogenesis, maternal administration of a chemical known to specifically inhibit PHS-1 'in vitro' resulted in potentiation of phenytoin teratogenicity, suggesting that these inhibitors may not be suitable for 'in vivo' use during pregnancy. The once-abandoned human teratogen thalidomide has found new therapeutic uses, even though its mechanism of teratogenesis remains unclear. In rabbits (a susceptible species), thalidomide initiated embryonic DNA oxidation and teratogenicity, both of which were abolished by pretreatment with PBN. Conversely, in mice (a resistant species) thalidomide did not enhance DNA oxidation, providing the first insight into an embryonic determinant of species-dependent susceptibility. These results constitute the first direct evidence that the teratogenicity of thalidomide may involve free radical-mediated oxidative damage to embryonic cellular macromolecules. The results from this thesis suggest that the mechanism of teratogenesis for many xenobiotics may involve embryonic PHS-catalyzed bioactivation to a free radical intermediate, resulting in ROS-dependent oxidative damage to embryonic cellular macromolecules.Ph.D
Serum Biomarkers Reveal Long-term Cardiac Injury in Isoproterenol-treated African Green Monkeys
The assessment of cardiac toxicity
is a major challenge in both
drug development and clinical trials, and numerous marketed pharmaceuticals
have been removed from the market due to unpredicted cardiac effects.
Serum troponins are widely used indicators of cardiac injury; however,
they are short-lived and have not been validated in preclinical animal
models. In this study, we have used filter-aided sample preparation
(FASP) and tandem mass tag (TMT) labeling to investigate serum protein
alterations in isoproterenol-treated African green monkeys. Our results
showed that the combination of FASP and TMT labeling provided highly
reproducible and efficient sample preparation, which enables us to
identify and quantify serum proteins with high confidence. We focused
on the proteins that exhibit long-term alteration upon isoproterenol
injection and discovered nine proteins exhibiting significant changes
at 48 and 72 h postdosing. We further chose three proteins, serum
amyloid A (SAA), frutose biphosphate aldolase A (FBAA), and fetuin
A, for validation using enzyme-linked immunosorbent assay (ELISA).
The serum concentration of SAA showed a ∼50 fold increase,
while concentration of FBAA and fetuin A exhibited a significant decrease
accompanying isoproterenol-induced cardiotoxicity. This work provides
valuable insights for multimarker evaluation of long-term cardiac
injury
Serum Biomarkers Reveal Long-term Cardiac Injury in Isoproterenol-treated African Green Monkeys
The assessment of cardiac toxicity
is a major challenge in both
drug development and clinical trials, and numerous marketed pharmaceuticals
have been removed from the market due to unpredicted cardiac effects.
Serum troponins are widely used indicators of cardiac injury; however,
they are short-lived and have not been validated in preclinical animal
models. In this study, we have used filter-aided sample preparation
(FASP) and tandem mass tag (TMT) labeling to investigate serum protein
alterations in isoproterenol-treated African green monkeys. Our results
showed that the combination of FASP and TMT labeling provided highly
reproducible and efficient sample preparation, which enables us to
identify and quantify serum proteins with high confidence. We focused
on the proteins that exhibit long-term alteration upon isoproterenol
injection and discovered nine proteins exhibiting significant changes
at 48 and 72 h postdosing. We further chose three proteins, serum
amyloid A (SAA), frutose biphosphate aldolase A (FBAA), and fetuin
A, for validation using enzyme-linked immunosorbent assay (ELISA).
The serum concentration of SAA showed a ∼50 fold increase,
while concentration of FBAA and fetuin A exhibited a significant decrease
accompanying isoproterenol-induced cardiotoxicity. This work provides
valuable insights for multimarker evaluation of long-term cardiac
injury
Serum Biomarkers Reveal Long-term Cardiac Injury in Isoproterenol-treated African Green Monkeys
The assessment of cardiac toxicity
is a major challenge in both
drug development and clinical trials, and numerous marketed pharmaceuticals
have been removed from the market due to unpredicted cardiac effects.
Serum troponins are widely used indicators of cardiac injury; however,
they are short-lived and have not been validated in preclinical animal
models. In this study, we have used filter-aided sample preparation
(FASP) and tandem mass tag (TMT) labeling to investigate serum protein
alterations in isoproterenol-treated African green monkeys. Our results
showed that the combination of FASP and TMT labeling provided highly
reproducible and efficient sample preparation, which enables us to
identify and quantify serum proteins with high confidence. We focused
on the proteins that exhibit long-term alteration upon isoproterenol
injection and discovered nine proteins exhibiting significant changes
at 48 and 72 h postdosing. We further chose three proteins, serum
amyloid A (SAA), frutose biphosphate aldolase A (FBAA), and fetuin
A, for validation using enzyme-linked immunosorbent assay (ELISA).
The serum concentration of SAA showed a ∼50 fold increase,
while concentration of FBAA and fetuin A exhibited a significant decrease
accompanying isoproterenol-induced cardiotoxicity. This work provides
valuable insights for multimarker evaluation of long-term cardiac
injury
Serum Biomarkers Reveal Long-term Cardiac Injury in Isoproterenol-treated African Green Monkeys
The assessment of cardiac toxicity
is a major challenge in both
drug development and clinical trials, and numerous marketed pharmaceuticals
have been removed from the market due to unpredicted cardiac effects.
Serum troponins are widely used indicators of cardiac injury; however,
they are short-lived and have not been validated in preclinical animal
models. In this study, we have used filter-aided sample preparation
(FASP) and tandem mass tag (TMT) labeling to investigate serum protein
alterations in isoproterenol-treated African green monkeys. Our results
showed that the combination of FASP and TMT labeling provided highly
reproducible and efficient sample preparation, which enables us to
identify and quantify serum proteins with high confidence. We focused
on the proteins that exhibit long-term alteration upon isoproterenol
injection and discovered nine proteins exhibiting significant changes
at 48 and 72 h postdosing. We further chose three proteins, serum
amyloid A (SAA), frutose biphosphate aldolase A (FBAA), and fetuin
A, for validation using enzyme-linked immunosorbent assay (ELISA).
The serum concentration of SAA showed a ∼50 fold increase,
while concentration of FBAA and fetuin A exhibited a significant decrease
accompanying isoproterenol-induced cardiotoxicity. This work provides
valuable insights for multimarker evaluation of long-term cardiac
injury
Serum Biomarkers Reveal Long-term Cardiac Injury in Isoproterenol-treated African Green Monkeys
The assessment of cardiac toxicity
is a major challenge in both
drug development and clinical trials, and numerous marketed pharmaceuticals
have been removed from the market due to unpredicted cardiac effects.
Serum troponins are widely used indicators of cardiac injury; however,
they are short-lived and have not been validated in preclinical animal
models. In this study, we have used filter-aided sample preparation
(FASP) and tandem mass tag (TMT) labeling to investigate serum protein
alterations in isoproterenol-treated African green monkeys. Our results
showed that the combination of FASP and TMT labeling provided highly
reproducible and efficient sample preparation, which enables us to
identify and quantify serum proteins with high confidence. We focused
on the proteins that exhibit long-term alteration upon isoproterenol
injection and discovered nine proteins exhibiting significant changes
at 48 and 72 h postdosing. We further chose three proteins, serum
amyloid A (SAA), frutose biphosphate aldolase A (FBAA), and fetuin
A, for validation using enzyme-linked immunosorbent assay (ELISA).
The serum concentration of SAA showed a ∼50 fold increase,
while concentration of FBAA and fetuin A exhibited a significant decrease
accompanying isoproterenol-induced cardiotoxicity. This work provides
valuable insights for multimarker evaluation of long-term cardiac
injury